Get the Stockscreener App
9.25
2.01%
-0.19
Bicara Therapeutics Inc stock is traded at $9.25, with a volume of 632.53K.
It is down -2.01% in the last 24 hours and down -37.84% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$9.44
Open:
$9.33
24h Volume:
632.53K
Relative Volume:
0.90
Market Cap:
$504.50M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.22%
1M Performance:
-37.84%
6M Performance:
-55.51%
1Y Performance:
+0.00%
1-Day Range:
$8.98
$9.4653
1-Week Range:
$8.94
$10.30
52-Week Range:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-785-8308
Address
245 MAIN STREET, CAMBRIDGE
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
9.25 | 505.55M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire Inc.
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients - MSN
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - Insider Monkey
Bicara Therapeutics Inc. (NASDAQ:BCAX) Shares Bought by Millennium Management LLC - Defense World
159,043 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Northern Trust Corp - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Raised to Equal Weight at Wells Fargo & Company - Defense World
Stifel maintains Bicara stock Buy rating, $48 target post-ASCO - Investing.com Australia
Stifel maintains Bicara stock Buy rating, $48 target post-ASCO By Investing.com - Investing.com Canada
112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AG - Defense World
Bicara falls after early-stage trial data for head and neck cancer therapy - MSN
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics - MSN
Bicara Therapeutics (NASDAQ:BCAX) Stock Rating Lowered by Wall Street Zen - Defense World
Wells Fargo Upgrades Bicara Therapeutics (BCAX) - Nasdaq
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? - Benzinga
Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity (NASDAQ:BCAX) - Seeking Alpha
Biotech Soars On 'Unprecedented' Results, Slamming Its Rival - Investor's Business Daily
Wells Fargo Upgrades Bicara Therapeutics to Equal Weight From Underweight, $8 Price Target - marketscreener.com
Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo - TipRanks
Wells upgrades Bicara to Equal Weight with thesis played out - TipRanks
Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook - Benzinga
Bicara stock falls after data for lead drug (BCAX:NASDAQ) - Seeking Alpha
Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results - Benzinga
Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today? - TipRanks
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating - TipRanks
Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics - TipRanks
Bicara Therapeutics to present head and neck cancer study data - Investing.com Australia
ASCO25 abstract roundup: Roche's Itovebi cuts risk of death; Merus' bispecific impresses in HNSCC, while Bicara's disappoints - FirstWord Pharma
Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp - TipRanks
Bicara Therapeutics to present head and neck cancer study data By Investing.com - Investing.com Nigeria
Bicara Therapeutics stock tumbles on clinical trial data - Investing.com Australia
Bicara Therapeutics stock tumbles on clinical trial data By Investing.com - Investing.com Nigeria
Bicara Therapeutics Inc. Announces Updated Interim Data from Phase 1/1b Trial of Ficerafusp Alfa in Head and Neck Cancer Ahead of ASCO Presentation - Nasdaq
Bicara Therapeutics Announces Publication of an Abstract - GlobeNewswire
Research Analysts Set Expectations for BCAX FY2026 Earnings - Defense World
TD Cowen reiterates Buy on Bicara Therapeutics stock - Investing.com Australia
TD Cowen reiterates Buy on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
FY2025 EPS Forecast for Bicara Therapeutics Cut by Analyst - Defense World
HC Wainwright Has Lowered Expectations for Bicara Therapeutics (NASDAQ:BCAX) Stock Price - Defense World
Bicara Therapeutics price target lowered to $41 from $44 at H.C. Wainwright - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down on Analyst Downgrade - Defense World
The Manufacturers Life Insurance Company Has $508,000 Stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Q2 EPS Estimates for Bicara Therapeutics Lowered by Wedbush - Defense World
Bicara Therapeutics Inc.: Promising Clinical Trials and Stable Financial Outlook Support Buy Rating - TipRanks
H.C. Wainwright cuts Bicara Therapeutics stock target to $41 By Investing.com - Investing.com South Africa
Pentair To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
H.C. Wainwright cuts Bicara Therapeutics stock target to $41 - Investing.com
Cautious Outlook on Bicara Therapeutics Inc. Amid Uncertain Pipeline and Market Underperformance - TipRanks
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Meisner Lara | Chief Legal Officer |
Mar 14 '25 |
Sale |
12.90 |
79,146 |
1,021,211 |
0 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):